BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), an integrated biopharmaceutical company, utilizes crystallography and structure-based drug design to develop a deep pipeline of innovative therapeutics. Currently, the company is progressing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. The U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. have all formed strategic alliances with the company and validate its scientific foundation and the utility of its product candidates. For further information, visit the Company’s web site at www.biocryst.com .